As an R&D driven organization, Premier Biotech is intensely focused on pro-actively addressing the ever-changing trends in substance abuse. Introducing the Premier Bio-Dip kratom drug screen, the first rapid urine test on the market to detect the key active compound Mitragynine at 150 ng/mL. Our customers now have the ability to accurately screen for kratom, an emerging drug increasing in popularity and abuse.
What is Kratom?
Once considered a safe and natural analgesic, kratom is an emerging drug of abuse that while currently legal at the Federal level, as of April 2019, 10 states have taken action to ban Kratom as a “controlled” substance. Kratom can cause effects similar to both opioids and stimulants. Two compounds in kratom leaves, mitragynine and 7-ΓΕ½ΓΒ± hydroxymitragynine interact with opioid receptors in the brain, producing sedation, pleasure, and decreased pain, especially when users consume large amounts of the plant. When kratom is taken in small amounts, users report increased energy, sociability, and alertness instead of sedation.
Kratom can also cause uncomfortable and sometimes dangerous side effects. A report released by the Centers for Disease Control and Prevention linked 91 deaths in 27 states to kratom over an 18-month period. While the use of kratom is increasing and the dangers of abuse is becoming more apparent, in a little more than 92% of the reported deaths, other drugs were also present in the deceased system such as fentanyl and heroin. The people at the highest risk of kratom-involved deaths are those with a history of substance abuse.
Kratom (Mitragynine) Single-Dip